Expression of p53 as a biomarker of pazopanib efficacy in solitary fibrous tumours: translational analysis of a phase II trial.

Andrea NapolitanoDavid S MouraNadia HindiJose L Mondaza-HernandezJosé A Merino-GarciaRafael RamosGian Paolo DagradaSilvia StacchiottiFrancesco GrazianoBruno VincenziJavier Martin-Broto

Published in: Therapeutic advances in medical oncology (2022)

mRNA levels are associated with worse prognosis in the subset of aggressive SFT patients treated with pazopanib.

Keyphrases

poor prognosis
metastatic renal cell carcinoma
binding protein
open label
long non coding rna
randomized controlled trial
placebo controlled
study protocol